Ovarian Cancer
📧 Sign up to get email alerts when something new happens for Ovarian Cancer.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2020-08-20FDA Approved: TOPOTECAN HYDROCHLORIDE — Supplemental Application (Accord Healthcare, Inc.)
FDA approved Accord Healthcare's supplemental application for Topotecan Hydrochloride, a generic chemotherapy drug, supporting its labeling …
-
CLINICAL_TRIALS trial_result · 2020-08-20Clinical Trial Update: Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer [Phase 2]
Phase 2 trial evaluating cediranib plus olaparib in recurrent platinum-resistant ovarian cancer has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-08-11Clinical Trial Update: Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer [Phase 2]
Takeda-sponsored Phase 2 trial of Niraparib in advanced, relapsed ovarian cancer (including fallopian tube and primary peritoneal cancers) h…
-
CLINICAL_TRIALS trial_result · 2020-08-10Clinical Trial Update: Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer [Phase 3]
Phase 3 trial evaluating paclitaxel and carboplatin versus ifosfamide in newly diagnosed, persistent, or recurrent uterine, ovarian, fallopi…
-
EMA label_change · 2020-07-24Authorised uses of cancer medicine Yondelis unchanged following review of new data
The EMA review concluded that the authorised uses of Yondelis (trabectedin) remain unchanged after evaluating new data.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-07-22Clinical Trial Update: Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer [Phase 1, Phase 2]
This trial update reports Phase 1/2 results for the combination of cediranib and olaparib in recurrent ovarian, fallopian tube, or primary p…
-
CLINICAL_TRIALS trial_result · 2020-07-02Clinical Trial Update: Auranofin and Sirolimus in Treating Participants With Ovarian Cancer [Phase 2]
A Phase 2 trial evaluating the combination of Auranofin and Sirolimus in ovarian cancer was terminated, with results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-06-22Clinical Trial Update: A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab [Phase 1]
Phase 1 study evaluating MEDI4736 (durvalumab) in combination with tremelimumab has completed, with results posted.
-
CLINICAL_TRIALS trial_result · 2020-06-17Clinical Trial Update: A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer [Phase 2]
Phase 2 trial of prexasertib (LY2606368) in platinum-resistant or refractory recurrent ovarian cancer completed; results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-06-11Clinical Trial Update: A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy [Phase 3]
A Phase 3 study evaluating niraparib as maintenance therapy for advanced ovarian cancer after response to frontline platinum-based chemother…
-
CLINICAL_TRIALS trial_result · 2020-06-05Clinical Trial Update: A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression [Phase 2]
Phase 2 open-label study evaluating PD0332991 (palbociclib) as a selective CDK4/6 inhibitor in recurrent ovarian cancer with RB-proficiency …
-
CLINICAL_TRIALS trial_result · 2020-05-29Clinical Trial Update: Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer [Phase 3]
Phase 3 trial update on cytoreductive surgery with HIPEC using lobaplatin for advanced and recurrent epithelial ovarian cancer.
-
CLINICAL_TRIALS trial_result · 2020-05-22Clinical Trial Update: Diaphragmatic Resection And Gynecological Ovarian Neoplasm [Phase 4]
Phase 4 clinical trial update on diaphragmatic resection in ovarian cancer.
-
FDA approval · 2020-05-15FDA Approved: RUBRACA — Supplemental Application (pharmaand GmbH)
The FDA approved a supplemental application for RUBRACA (rucaparib) submitted by pharmaand GmbH.
-
CLINICAL_TRIALS trial_result · 2020-05-12Clinical Trial Update: Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant Ovarian Cancer [Phase 2]
Phase 2 trial comparing apatinib plus etoposide capsule versus apatinib alone in platinum-resistant ovarian cancer.
-
CLINICAL_TRIALS trial_result · 2020-05-04Clinical Trial Update: Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer [Phase 1, Phase 2]
Phase I/IIa trial update for a folate binding protein vaccine in ovarian cancer, with completed status across Phase 1 and Phase 2.
-
CLINICAL_TRIALS trial_result · 2020-04-09Clinical Trial Update: A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens [Phase 2]
Phase 2 clinical trial evaluating niraparib in ovarian cancer patients who had three or four prior chemotherapy regimens; study completed wi…
-
CLINICAL_TRIALS trial_result · 2020-04-08Clinical Trial Update: Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 2]
Phase 2 trial evaluating erlotinib in combination with carboplatin for recurrent ovarian, fallopian tube, or primary peritoneal cancer compl…
-
CLINICAL_TRIALS trial_result · 2020-04-06Clinical Trial Update: Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial Cancer [Phase 2]
Phase 2 clinical trial evaluating lurtotecan liposome in advanced or recurrent ovarian epithelial cancer has completed.
-
CLINICAL_TRIALS trial_result · 2020-04-06Clinical Trial Update: ISIS 5132 in Treating Patients With Metastatic or Recurrent Ovarian Cancer [Phase 2]
Phase 2 clinical trial update for ISIS 5132 in patients with metastatic or recurrent ovarian cancer.
-
CLINICAL_TRIALS trial_result · 2020-04-02Clinical Trial Update: Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer [Phase 3]
Phase 3 trial evaluating combination chemotherapy regimens for ovarian epithelial cancer, primary peritoneal cancer, and fallopian tube canc…
-
CLINICAL_TRIALS trial_result · 2020-03-25Clinical Trial Update: Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer [Phase 2]
Takeda-sponsored phase 2 trial evaluating niraparib as maintenance therapy in Japanese participants with relapsed ovarian cancer has complet…
-
CLINICAL_TRIALS trial_result · 2020-03-20Clinical Trial Update: Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors [Phase 1]
Phase I study of lurbinectedin in combination with paclitaxel, with or without bevacizumab, in selected advanced solid tumors (completed; re…
-
CLINICAL_TRIALS trial_result · 2020-03-17Clinical Trial Update: A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer [Phase 2]
Phase 2 trial update evaluating pembrolizumab combined with standard treatment in recurrent platinum-resistant ovarian cancer has completed;…
-
CLINICAL_TRIALS trial_result · 2020-03-12Clinical Trial Update: Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer [Phase 3]
Phase 3 trial comparing karenitecin to topotecan in advanced epithelial ovarian cancer has completed.